- Datum02.04.2025
- UhrzeitLäuft gerade
- Veranstalter
XTB
Stefan Salomon
Moderator
Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05 Aktie
Verkaufen
Kaufen
Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05 Chart
Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05 Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
6,88 %
Intraday
1,54 %
1 Woche
2,33 %
1 Monat
-26,67 %
Seit Jahresbeginn
-50,19 %
1 Jahr
-72,78 %
3 Jahre
-83,92 %
5 Jahre
-95,91 %
10 Jahre
Wikifolio
Passender Service zu Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Webinar zu Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,140-3,380
- Jahrestief / Hoch ($)1,140-2,230
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Keine Dividenden verfügbar
Termine von Cellectis Act.Nom.(Sp.ADRs)/1 EO -,05
Keine aktuellen Termine
Beschreibung
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
